Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers
NCT ID: NCT02815176
Last Updated: 2016-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2016-06-30
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy
NCT01233128
Analysis of Biomarkers From Patients With Chorioretinal Diseases
NCT02026843
Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy
NCT00803517
Comparison of OCTA Factors in Patients With or Without Amyloid Pathology: A Prospective Study
NCT05475158
Choroidal Venous Congestion Following Scleral Buckling - An Imaging Study
NCT07260097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Central serous chorioretinopathy
De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
Blood sampling
Sampling the blood including DNA to investigate the thrombotic profile
Polypoidal choroidal vasculopathy
De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
Blood sampling
Sampling the blood including DNA to investigate the thrombotic profile
Epiretinal membrane
Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
Blood sampling
Sampling the blood including DNA to investigate the thrombotic profile
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
Sampling the blood including DNA to investigate the thrombotic profile
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* neurosensory detachment in optical coherence tomography (OCT)
* focal leakage in fluorescein angiography (FAG) and/or late choroidal hyperpermeability in indocyanine green angiography (ICGA)
* PCV
* subretinal and/or sub-retinal pigment epithelial fluid in OCT
* branching vascular network and/or polyps in ICGA
* Control
* epiretinal membrane (ERM)
* without underlying systemic, ophthalmic disease other than ERM
Exclusion Criteria
* Previous history of CSC/PCV
* Previous history or evidence of intraocular inflammation including uveitis
* Co-existing retinal or choroidal diseases
* History of allergic reaction to fluorescein or indocyanine green dye
* Underlying systemic conditions that could affect the thrombotic profiles (e.g. diabetes, hypertension, metabolic syndrome, coronary artery disease, cerebrovascular diseases, stroke, chronic renal failure, current smoker, pregnancy, sleep disorder)
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kunho Bae, MD
Role: PRINCIPAL_INVESTIGATOR
Department of ophthalmology, Samsung medical center, Seoul, Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-02-109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.